Opposite effects of anandamide and n-arachidonoyl dopamine in the regulation of prostaglandin E2 and 8-iso-PGF2α formation in primary glial cells

Journal of Neurochemistry

Volumn 109, Issue 2, 2009, Pages 452-464

  Navarrete, Carmen M ^a   Fiebich, Bernd L ^b,c   De Vinuesa, Amaya García ^a   Hess, Sandra ^b   De Oliveira, Antonio C P ^b   Candelario Jalil, Eduardo ^d   Caballero, Francisco J ^a   Calzado, Marco A ^a   Muñoz, Eduardo ^a  

^a Facultad de Medicina de Córdoba   (Spain)

^b UNIVERSITY OF FREIBURG   (Germany)

^c VIVACELL BIOTECHNOLOGY GMBH   (Germany)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

8 iso PGF2 ; Glial cells; Microsomal prostaglandin E synthase 1; N arachidonoyl dopamine; Neuroinflammation; Prostaglandin E2

Indexed keywords

ANANDAMIDE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYCLOOXYGENASE 2; ENDOCANNABINOID; FREE RADICAL; LIPOPOLYSACCHARIDE; N ARACHIDONOYL DOPAMINE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; GLIA CELL; IN VITRO STUDY; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ARACHIDONIC ACIDS; CELL SURVIVAL; DINOPROSTONE; DOPAMINE; ISOMERISM; ISOPROSTANES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROGLIA; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 62649119220     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.05966.x     Document Type: Article

References (86)

1. Achiron A., Miron S., Lavie V., Margalit R. Biegon A. (2000) Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. 102, 26 31.
2. Aid S., Langenbach R. Bosetti F. (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J. Neuroinflammation. 5, 17.
3. Akundi R. S., Candelario-Jalil E., Hess S., Hull M., Lieb K., Gebicke-Haerter P. J. Fiebich B. L. (2005) Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia 51, 199 208.
4. Andersen J. K. (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10 (Suppl. S18 S25.
5. Bisogno T., Melck D., Bobrov M., Gretskaya N. M., Bezuglov V. V., De Petrocellis L. Di Marzo V. (2000) N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351 pt. 3, 817 824.
6. Blais V., Turrin N. P. Rivest S. (2005) Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J. Neurochem. 95, 1563 1574.
7. Bobrov M. Y., Lizhin A. A., Andrianova E. L., Gretskaya N. M., Frumkina L. E., Khaspekov L. G. Bezuglov V. V. (2008) Antioxidant and neuroprotective properties of N-arachidonoyldopamine. Neurosci. Lett. 431, 6 11.
8. Bresalier R. S., Sandler R. S., Quan H. et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092 1102.
9. Candelario-Jalil E., Akundi R. S., Bhatia H. S., Lieb K., Appel K., Munoz E., Hull M. Fiebich B. L. (2006) Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production. J. Neuroimmunol. 174, 39 51.
10. Candelario-Jalil E., Gonzalez-Falcon A., Garcia-Cabrera M., Leon O. S. Fiebich B. L. (2007a) Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J. Neurochem. 100, 1108 1120.
11. Candelario-Jalil E., de Oliveira A. C., Graf S., Bhatia H. S., Hull M., Munoz E. Fiebich B. L. (2007b) Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 4, 25.
12. Cernak I., Vink R., Natale J. et al. (2004) The "dark side" of endocannabinoids: a neurotoxic role for anandamide. J. Cereb. Blood Flow Metab. 24, 564 578.
13. Chen P., Hu S., Yao J., Moore S. A., Spector A. A. Fang X. (2005) Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc. Res. 69, 28 35.
14. Choi S. H., Langenbach R. Bosetti F. (2008) Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide- induced inflammatory response and brain injury. FASEB J. 22, 1491 1501.
15. Clapper J. R., Duranti A., Tontini A., Mor M., Tarzia G. Piomelli D. (2006) The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. Pharmacol. Res. 54, 341 344.
16. Clement A. B., Hawkins E. G., Lichtman A. H. Cravatt B. F. (2003) Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23, 3916 3923.
17. Craft J. M., Watterson D. M. Van Eldik L. J. (2005) Neuroinflammation: a potential therapeutic target. Expert Opin. Ther. Targets 9, 887 900.
18. De Petrocellis L., Melck D., Bisogno T. Di Marzo V. (2000) Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem. Phys. Lipids 108, 191 209.
19. Devane W. A., Hanus L., Breuer A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946 1949.
20. Di Marzo V., Bisogno T. De Petrocellis L. (2000) Endocannabinoids: new targets for drug development. Curr. Pharm. Des. 6, 1361 1380.
21. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A. Bisogno T. (2002) Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66, 377 391.
22. Di Marzo V., Bifulco M. De Petrocellis L. (2004) The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771 784.
23. Dickson D. W., Lee S. C., Mattiace L. A., Yen S. H. Brosnan C. (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7, 75 83.
24. Eljaschewitsch E., Witting A., Mawrin C. et al. (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49, 67 79.
25. Engblom D., Saha S., Engstrom L., Westman M., Audoly L. P., Jakobsson P. J. Blomqvist A. (2003) Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat. Neurosci. 6, 1137 1138.
26. Fahmi H. (2004) mPGES-1 as a novel target for arthritis. Curr. Opin. Rheumatol. 16, 623 627.
27. Fiebich B. L., Lieb K., Kammerer N. Hull M. (2003) Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia. J. Neurochem. 86, 173 178.
28. Fogli S., Nieri P., Chicca A., Adinolfi B., Mariotti V., Iacopetti P., Breschi M. C. Pellegrini S. (2006) Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 580, 1733 1739.
29. Fowler C. J. Tiger G. (2005) Cyclooxygenation of the arachidonoyl side chain of 1-arachidonoylglycerol and related compounds block their ability to prevent anandamide and 2-oleoylglycerol metabolism by rat brain in vitro. Biochem. Pharmacol. 69, 1241 1245.
30. Giuliano M., Calvaruso G., Pellerito O., Portanova P., Carlisi D., Vento R. Tesoriere G. (2006) Anandamide-induced apoptosis in Chang liver cells involves ceramide and JNK/AP-1 pathway. Int. J. Mol. Med. 17, 811 819.
31. Griffin D. E., Wesselingh S. L. McArthur J. C. (1994) Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann. Neurol. 35, 592 597.
32. Guzman M., Sanchez C. Galve-Roperh I. (2001) Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78, 613 625.
33. Hansen H. H., Schmid P. C., Bittigau P. et al. (2001) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 1415 1427.
34. Hewett S. J., Silakova J. M. Hewett J. A. (2006) Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration. J.Pharmacol Exp.Ther. 319, 1219 1224.
35. Hinz B., Ramer R., Eichele K., Weinzierl U. Brune K. (2004) Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol. Pharmacol. 66, 1643 1651.
36. Hoozemans J. J., Veerhuis R., Rozemuller J. M. Eikelenboom P. (2006) Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int. J. Dev. Neurosci. 24, 157 165.
37. Howlett A. C. Mukhopadhyay S. (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108, 53 70.
38. Huang S. M., Bisogno T., Trevisani M. et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA 99, 8400 8405.
39. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., Morham S. Ross M. E. (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl Acad. Sci. USA 98, 1294 1299.
40. Ikeda-Matsuo Y., Ota A., Fukada T., Uematsu S., Akira S. Sasaki Y. (2006) Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc. Natl Acad. Sci. USA 103, 11790 11795.
41. Jackson S. J., Diemel L. T., Pryce G. Baker D. (2005) Cannabinoids and neuroprotection in CNS inflammatory disease. J. Neurol. Sci. 233, 21 25.
42. Jakobsson P. J., Thoren S., Morgenstern R. Samuelsson B. (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl Acad. Sci. USA 96, 7220 7225.
43. Kawano T., Anrather J., Zhou P. et al. (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 12, 225 229.
44. Kim H. J., Chung J. I., Lee S. H., Jung Y. S., Moon C. H. Baik E. J. (2008) Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res. 1193, 153 161.
45. Kozak K. R., Rowlinson S. W. Marnett L. J. (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 275, 33744 33749.
46. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A. Czlonkowska A. (1999) MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol. Exp. (Wars) 59, 1 8.
47. Liu B. Hong J. S. (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1 7.
48. Malfitano A. M., Matarese G., Pisanti S., Grimaldi C., Laezza C., Bisogno T., Di Marzo V., Lechler R. I. Bifulco M. (2006) Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J. Neuroimmunol. 171, 110 119.
49. Malfitano A. M., Laezza C., Pisanti S., Gazzerro P. Bifulco M. (2008) Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br. J. Pharmacol. 153, 1003 1010.
50. Marsicano G., Goodenough S., Monory K. et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science, 302, 84 88.
51. McAllister S. D. Glass M. (2002) CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66, 161 171.
52. McGeer P. L., Itagaki S., Boyes B. E. McGeer E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285 1291.
53. Minghetti L. (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63, 901 910.
54. Minghetti L. (2005) Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18, 315 321.
55. Minghetti L. Levi G. (1998) Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog. Neurobiol. 54, 99 125.
56. Montine T. J., Sidell K. R., Crews B. C., Markesbery W. R., Marnett L. J., Roberts L. J. 2nd. Morrow J. D. (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495 1498.
57. Movsesyan V. A., Stoica B. A., Yakovlev A. G., Knoblach S. M., Lea P. M., IV., Cernak I., Vink R. Faden A. I. (2004) Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ. 11, 1121 1132.
58. Murakami M., Naraba H., Tanioka T. et al. (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275, 32783 32792.
59. Naraba H., Yokoyama C., Tago N., Murakami M., Kudo I., Fueki M., Oh-Ishi S. Tanabe T. (2002) Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J. Biol. Chem. 277, 28601 28608.
60. Nogawa S., Zhang F., Ross M. E. Iadecola C. (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17, 2746 2755.
61. Nussmeier N. A., Whelton A. A., Brown M. T., Langford R. M., Hoeft A., Parlow J. L., Boyce S. W. Verburg K. M. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081 1091.
62. de Oliveira A. C., Candelario-Jalil E., Bhatia H. S., Lieb K., Hull M. Fiebich B. L. (2008) Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia 56, 844 855.
63. Pepicelli O., Fedele E., Berardi M., Raiteri M., Levi G., Greco A., Ajmone-Cat M. A. Minghetti L. (2005) Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-D-aspartate receptors in rat hippocampus. J. Neurochem. 93, 1561 1567.
64. Pratico D., Barry O. P., Lawson J. A., Adiyaman M., Hwang S. W., Khanapure S. P., Iuliano L., Rokach J. FitzGerald G. A. (1998) IPF2alpha-I: an index of lipid peroxidation in humans. Proc. Natl Acad. Sci. USA 95, 3449 3454.
65. Pryce G., Ahmed Z., Hankey D. J. et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191 2202.
66. Sancho R., Calzado M. A., Di Marzo V., Appendino G. Munoz E. (2003) Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol. Pharmacol. 63, 429 438.
67. Sancho R., Macho A., de La Vega L., Calzado M. A., Fiebich B. L., Appendino G. Munoz E. (2004) Immunosuppressive activity of endovanilloids: N-arachidonoyl-dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J. Immunol. 172, 2341 2351.
68. Sarker K. P., Obara S., Nakata M., Kitajima I. Maruyama I. (2000) Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 472, 39 44.
69. Sasaki T., Kitagawa K., Yamagata K., Takemiya T., Tanaka S., Omura-Matsuoka E., Sugiura S., Matsumoto M. Hori M. (2004) Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J. Cereb. Blood Flow Metab. 24, 107 113.
70. Sherman M. P., Griscavage J. M. Ignarro L. J. (1992) Nitric oxide-mediated neuronal injury in multiple sclerosis. Med. Hypotheses 39, 143 146.
71. Siegmund S. V., Seki E., Osawa Y., Uchinami H., Cravatt B. F. Schwabe R. F. (2006) Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J. Biol. Chem. 281, 10431 10438.
72. Sinor A. D., Irvin S. M. Greenberg D. A. (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278, 157 160.
73. Solomon S. D., McMurray J. J., Pfeffer M. A. et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071 1080.
74. van der Stelt M., Veldhuis W. B., van Haaften G. W. et al. (2001) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 8765 8771.
75. Takemiya T., Matsumura K. Yamagata K. (2007) Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochem. Int. 51, 112 120.
76. Tanikawa N., Ohmiya Y., Ohkubo H., Hashimoto K., Kangawa K., Kojima M., Ito S. Watanabe K. (2002) Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem. Biophys. Res. Commun. 291, 884 889.
77. Tanioka T., Nakatani Y., Semmyo N., Murakami M. Kudo I. (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol.Chem. 275, 32775 32782.
78. Teismann P., Tieu K., Choi D. K., Wu D. C., Naini A., Hunot S., Vila M., Jackson-Lewis V. Przedborski S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473 5478.
79. Tham C. S., Whitaker J., Luo L. Webb M. (2007) Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett. 581, 2899 2904.
80. Toscano C. D., Ueda Y., Tomita Y. A., Vicini S. Bosetti F. (2008) Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice. Brain Res.Bull. 75, 598 609.
81. Tseng C. F., Iwakami S., Mikajiri A., Shibuya M., Hanaoka F., Ebizuka Y., Padmawinata K. Sankawa U. (1992) Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine and N-acyldopamine derivatives. Chem. Pharm. Bull. (Tokyo) 40, 396 400.
82. Vijitruth R., Liu M., Choi D. Y., Nguyen X. V., Hunter R. L. Bing G. (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J.Neuroinflammation. 3, 6.
83. Watanabe K., Kurihara K. Suzuki T. (1999) Purification and characterization of membrane-bound prostaglandin E synthase from bovine heart. Biochim. Biophys. Acta 1439, 406 414.
84. Weber A., Ni J., Ling K. H., Acheampong A., Tang-Liu D. D., Burk R., Cravatt B. F. Woodward D. (2004) Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J. Lipid Res. 45, 757 763.
85. Yamagata K., Matsumura K., Inoue W. et al. (2001) Coexpression of microsomal-type prostaglandin E synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever. J. Neurosci. 21, 2669 2677.
86. Yu M., Ives D. Ramesha C. S. (1997) Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem. 272, 21181 21186.